[POST-TREATMENT SURVEY OF THE MAINTENANCE OF EFFECTS FOR CEDAR SUBLINGUAL IMMUNOTHERAPY].

Q4 Medicine

Japanese Journal of Allergology Pub Date : 2026-01-01 DOI:10.15036/arerugi.75.132

Atsushi Yuta, Yukiko Ogawa, Hideaki Kozaki, Koji Matsumoto, Takeshi Shimizu, Mitsuhiro Okano

{"title":"[POST-TREATMENT SURVEY OF THE MAINTENANCE OF EFFECTS FOR CEDAR SUBLINGUAL IMMUNOTHERAPY].","authors":"Atsushi Yuta, Yukiko Ogawa, Hideaki Kozaki, Koji Matsumoto, Takeshi Shimizu, Mitsuhiro Okano","doi":"10.15036/arerugi.75.132","DOIUrl":null,"url":null,"abstract":"We studied post-treatment survey of the maintenance of effects for cedar sublingual immunotherapy (SLIT).Methods: Patients who started between 2018 and 2020 and had completed at least three seasons of SLIT with Cedarcure (post-SLIT patients) were surveyed by mail in 2025, regarding as 1) impressions compared to the time of SLIT completion, 2) the VAS (best 0-worst 100mm) of general symptoms in pollen season at 3 points (pre-SLIT, at the end of SLIT and in 2025), 3) medication score. Responses were received from 200 of 370 patients (age 15 [11-42] years, male 97).Results: The percentages of the maintenance of effects were 61%, 59%, 51% and 34% in order of 1- to 4-year follow-up, respectively (p<0.05 in 4-year vs 1- or 2-year, unadjusted and uncorrected). The VAS for all patients changed 90→10→20 in median at the three time points. On the 2025 VAS, the 4-year follow-up was significantly worse than the 1- and 2-year follow-ups, and the SLIT treated for 3 years was significantly worse than for 4 or 5 years (p<0.05). Compared with currently undergoing SLIT with the same treatment duration, the VAS of post-SLIT patients was significantly worsened in the group of 3 years of treatment, but not in the group of 4 or 5 years. The medication score was 0.3 in median, and there was no difference with currently SLIT patients.Conclusion: Although many patients progressed well, some cases worsened, and the four-year follow-up was significantly worse. A four-year or more treatment is recommended.","PeriodicalId":35521,"journal":{"name":"Japanese Journal of Allergology","volume":"75 2","pages":"132-141"},"PeriodicalIF":0.0000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Allergology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15036/arerugi.75.132","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

We studied post-treatment survey of the maintenance of effects for cedar sublingual immunotherapy (SLIT).

Methods: Patients who started between 2018 and 2020 and had completed at least three seasons of SLIT with Cedarcure (post-SLIT patients) were surveyed by mail in 2025, regarding as 1) impressions compared to the time of SLIT completion, 2) the VAS (best 0-worst 100mm) of general symptoms in pollen season at 3 points (pre-SLIT, at the end of SLIT and in 2025), 3) medication score. Responses were received from 200 of 370 patients (age 15 [11-42] years, male 97).

Results: The percentages of the maintenance of effects were 61%, 59%, 51% and 34% in order of 1- to 4-year follow-up, respectively (p<0.05 in 4-year vs 1- or 2-year, unadjusted and uncorrected). The VAS for all patients changed 90→10→20 in median at the three time points. On the 2025 VAS, the 4-year follow-up was significantly worse than the 1- and 2-year follow-ups, and the SLIT treated for 3 years was significantly worse than for 4 or 5 years (p<0.05). Compared with currently undergoing SLIT with the same treatment duration, the VAS of post-SLIT patients was significantly worsened in the group of 3 years of treatment, but not in the group of 4 or 5 years. The medication score was 0.3 in median, and there was no difference with currently SLIT patients.

Conclusion: Although many patients progressed well, some cases worsened, and the four-year follow-up was significantly worse. A four-year or more treatment is recommended.

查看原文本刊更多论文

[雪松舌下免疫治疗后疗效维持情况调查]。

我们研究了雪松舌下免疫治疗（SLIT）的治疗后疗效维持情况。方法：对2018年至2020年间开始使用Cedarcure完成至少三季SLIT的患者（SLIT后患者）于2025年进行邮寄调查，包括：1)与SLIT完成时间相比的印象，2)花粉季节3点（SLIT前，SLIT结束时和2025年）一般症状的VAS（最佳0-最差100mm）， 3)药物评分。370例患者（年龄15[11-42]岁，男性97例）中有200例患者回复。结果：1 ~ 4年随访效果维持率依次为61%、59%、51%、34%。(结论：虽然很多患者进展良好，但也有部分患者病情恶化，4年随访明显恶化。建议四年或更长时间的治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Japanese Journal of Allergology Medicine-Immunology and Allergy

CiteScore

0.30

自引率

0.00%

发文量

期刊介绍： The Japanese Society of Allergology is made up of medical researchers and clinical physicians who share an involvement in the study of allergies and clinical immunology. Clinical subspecialties include such allergies and immune-response disorders as bronchial asthma, hypersensitivity pneumonitis, collagen disease, allergic rhinitis, pollenosis, hives, atopic dermatitis, and immunodeficiency. However, there are many patients afflicted by other allergies as well. The Society considers all such patients and disorders within its purview.